If you are not happy with the results below please do another search
A remarkable discovery and collaborative effort have revealed a new type of triterpenes, a group of organic compounds which are an important source of many medicines. Until now, all triterpenes were believed to be derived from squalene, itself a type of triterpene. However, for the first time, researchers witnessed biosynthesis, the formation of complex compounds […]
CYTENA, a BICO group company and a leading provider of high-precision instruments for handling biological cells, has entered a collaboration agreement with ExcellGene SA, a leading biologics Contract Development & Manufacturing Organization (CDMO) that manufactures recombinant proteins. Together, the companies will streamline cell line development workflows for highly-efficient monoclonal antibody (mAb) and complex therapeutic protein […]
Xyall, a global innovator in molecular pathology, has attracted a Series B investment of €6 million to accelerate commercialization of its Tissector High Throughput and Tissector Table Top systems.
KNAUER Wissenschaftliche Geräte, a developer of laboratory instruments and known for their liquid chromatography systems and components, was honoured with the German Innovation Award 2022 in Munich in April for their design and manufacture of large-scale plants, at its own risk, for the ncapsulation of mRNA for COVID-19 vaccines. Equipment for the production of millions of mRNA vaccine doses had […]
Dr Stefan Gebauer has taken over management of the “Preanalytics” product division at Greiner Bio-One in Kremsmünster, Austria. He has many years of professional and management experience in the healthcare industry, focussing primarily on medical products in the IVD sector. Before joining Greiner Bio-One, he successfully managed the “Therapy Management” product line at Bosch Healthcare […]
Agilent Technologies says its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with KEYTRUDA (pembrolizumab) may be appropriate.
Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has extended its collaboration agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, to develop four new Optimer-drug conjugates for use as precision chemotherapeutics.
Avacta Group, a clinical stage oncology drug company developing cancer therapies and diagnostics based on its proprietary pre|CISION and Affimer platforms, has relocated its Therapeutics division to a new headquarters at Scale Space, in Imperial College’s White City Campus, London.
Wake Forest Institute for Regenerative Medicine (WFIRM) scientists working on CRISPR/Cas9-mediated gene editing technology have developed a method to increase efficiency of editing while minimizing DNA deletion sizes, a key step toward developing gene editing therapies to treat genetic diseases.
A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has discovered a new molecular pathway to govern melanoma angiogenesis and metastasis. The findings provide new insights into how melanoma undergoes metastasis and progression through secretion of pro-angiogenic factor to induce angiogenesis that paves the way for new therapeutic opportunities. The […]
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
